Related Experiment Video

Updated: Jul 11, 2026

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting

Raffaella Giavazzi1, Maria Rosa Bani, Giulia Taraboletti

  • 1Laboratory of Biology and Treatment of Metastasis, Department of Oncology, Mario Negri Institute for Pharmacological Research, Bergamo, Italy. giavazzi@marionegri.it

Cancer Metastasis Reviews
|September 27, 2007
PubMed

Insights

Combining paclitaxel with anti-angiogenic drugs or vascular disrupting agents shows promise for cancer treatment. Optimizing drug scheduling and sequencing is crucial for maximizing efficacy and minimizing negative interactions.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Therapeutics

Background:

  • Targeting tumor stroma, including vasculature, is a novel approach in cancer treatment.
  • Stroma-directed therapies require combination with conventional treatments for efficacy.

Purpose of the Study:

  • To review preclinical experiences combining paclitaxel with angiogenesis inhibitors (SU6668) and vascular disrupting agents (ZD6126).
  • To discuss critical factors influencing treatment outcomes in combination therapies.

Main Methods:

  • Review of preclinical data on combination therapies involving paclitaxel.
  • Analysis of drug sensitivity, synergistic effects on vasculature, and independent targeting of host/tumor compartments.
  • Discussion on optimizing scheduling and sequencing of combined agents.

Main Results:

  • Preclinical studies explored combinations of paclitaxel with SU6668 and ZD6126.
  • Factors like tumor sensitivity and drug interaction critically affect outcomes.
  • Synergistic or independent effects on vasculature and tumor compartments were analyzed.

Conclusions:

  • Combination of paclitaxel with novel agents like SU6668 and ZD6126 requires careful optimization.
  • Optimizing scheduling and sequencing is essential to avoid negative interactions and enhance antineoplastic efficacy.
  • Further research into reliable endpoints is needed for effective combination treatment strategies.

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...